Fut8 Knockout Cell Line (CHO-K1)

The choice depends on whether you are studying Fut8 (α-1,6-fucosyltransferase 8)'s role as the principal core fucosyltransferase or modeling the industrial application of afucosylated antibody production. The Knockout line is the standard tool for asking whether Fut8 is required for core fucosylation — Fut8 catalyzes the addition of fucose to the innermost GlcNAc of N-glycan chains via α-1,6 linkage, generating 'core fucosylation' that is present on most mammalian N-glycoproteins including the IgG Fc region. Overexpression is useful for studying Fut8 in heterologous contexts. For biopharmaceutical research, the EDITGENE Fut8 Knockout in CHO-K1 is the industry-standard platform — CHO-K1 is the principal cell line for recombinant antibody production, and Fut8 KO generates afucosylated antibodies with enhanced ADCC activity (the basis of POTELLIGENT and similar industrial platforms). Mogamulizumab (anti-CCR4 for cutaneous T-cell lymphoma) and other approved afucosylated antibodies were produced in Fut8-defective CHO-K1-derived lines. Rescue with wild-type Fut8 restores fucosylation. The knockout is uniquely valuable for studying core fucosylation biology and producing afucosylated therapeutic antibodies with enhanced effector function.

Primary applications: • Afucosylated antibody production: industrial-scale production of monoclonal antibodies with enhanced ADCC activity in the Fut8 KO CHO-K1 platform. • Core fucosylation analysis: mass spectrometry analysis of N-glycan fucosylation status of expressed glycoproteins. • ADCC enhancement: FcγRIIIa binding affinity and NK cell-mediated ADCC activity comparison between fucosylated versus afucosylated antibodies produced from the parental and KO lines. • Biosimilar/biobetter development: afucosylated variant production of existing therapeutic antibodies for ADCC-enhanced biobetter strategies. EDITGENE recommends this model as the industry-standard platform for afucosylated antibody production and core fucosylation biology research.

Yes. Fut8 rescue experiments are well-established for glycoengineering research: • Construct design: use a codon-modified Fut8 sequence with a small C-terminal tag (FLAG, HA). Fut8 has N-terminal cytosolic tail, single transmembrane span (Golgi anchor), stem region, and C-terminal catalytic domain — preserve Golgi-anchoring architecture. • Catalytically-dead rescue: GDP-fucose-binding or substrate-binding pocket mutations abolish fucosyltransferase activity. • Rescue validates KO specificity: WT Fut8 rescue restores core fucosylation, providing on-target controls for the afucosylated antibody platform. • Functional readout: rescue should restore N-glycan core fucosylation measured by mass spectrometry and LCA (Lens culinaris agglutinin) lectin binding. CHO-K1-specific considerations: • CHO-K1 is a Chinese hamster ovary cell line — the principal industrial cell line for recombinant therapeutic protein production, including monoclonal antibodies. • Lentiviral transduction is supported with moderate efficiency. • Fut8 KO in CHO-K1 generates an afucosylated production platform — antibodies produced from this line lack core fucose, conferring enhanced ADCC activity (the basis of POTELLIGENT and similar industrial platforms).